| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/24/2002 | WO2002083262A1 Cell separation compositions and methods |
| 10/24/2002 | WO2002083241A1 Single dose aromatase inhibitor for treating infertility |
| 10/24/2002 | WO2002083240A1 Aromatase inhibition to enhance assisted reproduction |
| 10/24/2002 | WO2002083239A1 Aromatase inhibitors for treating infertility |
| 10/24/2002 | WO2002083222A1 Device for artificial respiration |
| 10/24/2002 | WO2002083192A1 Articles comprising a mint odor-free cooling agent |
| 10/24/2002 | WO2002083184A2 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
| 10/24/2002 | WO2002083180A1 Elongated and multiple spacers in activatible prodrugs |
| 10/24/2002 | WO2002083178A1 Pharmaceutical composition based on macrolides for topical application in ophthalmology |
| 10/24/2002 | WO2002083177A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine |
| 10/24/2002 | WO2002083175A1 Visual function improving agents |
| 10/24/2002 | WO2002083173A1 Use of an histone deacetylase inhibitor for the treatment of diseases associated with an hpv infection |
| 10/24/2002 | WO2002083155A1 Use of sulfated bacterial polysaccharides suitable for the inhibition of angiogenesis |
| 10/24/2002 | WO2002083154A1 Use of cationic dextran derivatives for protecting dose-limiting organs |
| 10/24/2002 | WO2002083153A1 Method and composition for controlled release acarbose formulations |
| 10/24/2002 | WO2002083152A1 Activation of natural killer cells by adenosine a3 receptor agonists |
| 10/24/2002 | WO2002083151A2 Compositions and methods for treating an arthritic condition |
| 10/24/2002 | WO2002083150A1 Bisphosphonate conjugates and methods of making and using the same |
| 10/24/2002 | WO2002083149A1 Drugs fo rpromoting the proliferation, differentiation and/or survival of glial cells containing cyclic phosphatidic acid |
| 10/24/2002 | WO2002083148A1 Nerve cell survival promoters containing cyclic phosphatidic acid derivative |
| 10/24/2002 | WO2002083147A1 Use of bile acid or bile salt fatty acid conjugates |
| 10/24/2002 | WO2002083146A1 Multiple dose aromatase inhibitor for treating infertility |
| 10/24/2002 | WO2002083145A1 N-biphenylcarbonyl- and n-phenylpyridylcarbonyl substituted bi- and tricyclic azepines and diazepines as vasopressing agonists |
| 10/24/2002 | WO2002083144A1 Method of treatment using deuterium compounds |
| 10/24/2002 | WO2002083143A1 Cxcr3 antagonists |
| 10/24/2002 | WO2002083142A1 Novel use of arylethenesulfonamide derivative |
| 10/24/2002 | WO2002083141A1 Treatment of fibromyalgia and chronic fatigue syndrome |
| 10/24/2002 | WO2002083139A1 Inhibitors of akt activity |
| 10/24/2002 | WO2002083138A1 Inhibitors of akt activity |
| 10/24/2002 | WO2002083137A1 Use of npy y2 receptor antagonists |
| 10/24/2002 | WO2002083136A1 Therapeutic compositions comprising amino sulfonic acids and their uses |
| 10/24/2002 | WO2002083135A2 Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence |
| 10/24/2002 | WO2002083134A1 Aryl and biaryl piperidines used as mch antagonists |
| 10/24/2002 | WO2002083133A1 Novel oral general anesthetics and metabolitically resistant anticonvulsants |
| 10/24/2002 | WO2002083132A1 Gastric acid secretion inhibiting composition |
| 10/24/2002 | WO2002083131A1 Activators and ligands of ppar-beta/delta for the treatment of skin conditions |
| 10/24/2002 | WO2002083130A1 Enantiomers of n-[[2'-[[(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-n,3,3-trimethylbutanamide |
| 10/24/2002 | WO2002083129A2 Pharmaceutical composition comprising clavulanic acid |
| 10/24/2002 | WO2002083128A1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method |
| 10/24/2002 | WO2002083127A1 Protein modification-inhibitory compositions |
| 10/24/2002 | WO2002083126A1 Phenylindoles for the treatment of hiv |
| 10/24/2002 | WO2002083125A1 Method of inhibiting adhesion formation |
| 10/24/2002 | WO2002083124A1 A composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin |
| 10/24/2002 | WO2002083123A1 Aurones as telomerase inhibitors |
| 10/24/2002 | WO2002083122A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation |
| 10/24/2002 | WO2002083121A1 Compositions for improving skin environment and clothes thereof |
| 10/24/2002 | WO2002083120A2 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors |
| 10/24/2002 | WO2002083119A1 Pharmaceutical composition comprising ibuprofen and prochlorperazine |
| 10/24/2002 | WO2002083118A1 Concentrated aqueous solution of ibuprofen |
| 10/24/2002 | WO2002083117A1 Toluene sulfonamide-containing anti-tumor composition and method of use thereof |
| 10/24/2002 | WO2002083116A1 Methods of treating prion disease in mammals comprising administering a chaotropic agent such as guanidine, urea or potassium iodide |
| 10/24/2002 | WO2002083115A1 Treatment of disorders secondary to organic impairments |
| 10/24/2002 | WO2002083114A1 Pharmaceutical compositiong or preventing and treating cancer and treating an inflammation |
| 10/24/2002 | WO2002083113A2 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization |
| 10/24/2002 | WO2002083112A2 Method for the treatment of polycystic kidney disease |
| 10/24/2002 | WO2002083111A2 Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence |
| 10/24/2002 | WO2002083110A2 Animal model for evaluating analgesics |
| 10/24/2002 | WO2002083109A1 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv |
| 10/24/2002 | WO2002083108A2 Compositions containing cgmp pde inhibitors and local anaesthetic agents for nasal application |
| 10/24/2002 | WO2002083107A1 Adhesive emulsion for medical purposes made from ethylene-vinyl acetate copolymers and adhesive resins |
| 10/24/2002 | WO2002083106A1 Controlled delivery of tetracycline compounds and tetracycline derivatives |
| 10/24/2002 | WO2002083105A2 Composition for enhanced absorption of nsaids |
| 10/24/2002 | WO2002083104A1 An effervescent solid composition of matter |
| 10/24/2002 | WO2002083103A2 Pharmaceutical product with reticulated crystalline microstructure |
| 10/24/2002 | WO2002083101A1 Controlled-release nimodipine tablet and method for producing the same |
| 10/24/2002 | WO2002083098A1 Coenzyme q10 containing microemulsion preconcentrates and microemulsions |
| 10/24/2002 | WO2002083096A1 Modification of the sustained release profile |
| 10/24/2002 | WO2002083087A1 Sugar intake promoters |
| 10/24/2002 | WO2002083086A1 Pharmaceutical compositions of topic use, applied in treatment of skin and/or mucous injuries; use of compositions in treatment of skin and/or mucous injuries and use of compounds in treatment of skin and/or mucous injuries |
| 10/24/2002 | WO2002083084A1 Nail compositions and methods of administering same |
| 10/24/2002 | WO2002083083A2 Pharmaceutically active compounds and methods of use |
| 10/24/2002 | WO2002083079A2 Aerosol compositions containing formoterol for delivery to the lungs via nebulization |
| 10/24/2002 | WO2002083075A2 Akt and regulation of ra synovial fibroblast apoptosis |
| 10/24/2002 | WO2002083074A2 Methods for the treatment of hepatic disorders |
| 10/24/2002 | WO2002083067A2 Prodrugs via acylation with cinnamate |
| 10/24/2002 | WO2002083066A2 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| 10/24/2002 | WO2002083064A2 A method of treating cancer |
| 10/24/2002 | WO2002083061A2 The use of beta 1,3 - glucan - containing compositions to potentiate immune responses ______________________________________________ |
| 10/24/2002 | WO2002083060A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs |
| 10/24/2002 | WO2002083059A2 Use of esters of long-chain fatty acids for treatment of autoimmune diseases |
| 10/24/2002 | WO2002082929A1 Improved edible compositions for lowering cholesterol |
| 10/24/2002 | WO2002082904A2 Method of treating or retarding the development of blindness |
| 10/24/2002 | WO2002076470A8 External skin compositions |
| 10/24/2002 | WO2002074763A9 Benzimidazol derivatives modulate chemokine receptors |
| 10/24/2002 | WO2002066078A3 Modulated release particles for aerosol delivery |
| 10/24/2002 | WO2002066077A3 Modulated release particles for aerosol delivery |
| 10/24/2002 | WO2002066035A3 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 10/24/2002 | WO2002066019A3 Cancer treatment |
| 10/24/2002 | WO2002064618A9 Methods of identifying agents that mediate polypeptide aggregation |
| 10/24/2002 | WO2002064557A3 New crystal forms of oxcarbazepine and processes for their preparation |
| 10/24/2002 | WO2002062386A3 Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration |
| 10/24/2002 | WO2002062325A8 Method of treating conditions related to platelet activity |
| 10/24/2002 | WO2002062310B1 Multifunctional particulate additive for personal care and cosmetic compositions, and the process of making the same |
| 10/24/2002 | WO2002062300A3 Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
| 10/24/2002 | WO2002060931A3 A fimbria-like gene in bifidobacteria |
| 10/24/2002 | WO2002060534A3 Selective alpha 1 antagonists a + d |
| 10/24/2002 | WO2002058639A3 Pyranoflavonoid compounds and their use as estrogen receptor modulators |
| 10/24/2002 | WO2002057253A3 Isoindolyl and isoquinolinyl aroyl pyrrole compounds for the treatment of central nervous system disorders |
| 10/24/2002 | WO2002055522A3 Novel multi-ring organic compounds for regulating gut motility and food intake |
| 10/24/2002 | WO2002053140A3 New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |